-
Has your office telephone been ringing with questions from patients following a recent media report that the death rate for the transdermal contraceptive (Ortho Evra, Ortho-McNeil Pharmaceutical, Raritan, NJ) is three times that expected for oral contraceptives?
-
If emergency contraception (EC) is made available over the counter (OTC) in the United States, will it lead to more unprotected sex and increased use? Results from a just-published analysis of British use of the drug indicates that it will not.
-
How do you initiate mini-pills in a lactating woman who specifies such pill use for contraception?
-
Take a look at www.trichomoniasis.net, the first comprehensive web site to focus on the sexually transmitted disease (STD) trichomoniasis.
-
No doubt you have scanned news reports of a recent study of male circumcision, used as an HIV prevention intervention, which resulted in dramatic reduction in HIV incidence among circumcised men.1 But does the news translate into an immediate change in public health policy?
-
The manufacturer of the abortion pill mifepristone (Mifeprex, Danco Laboratories; New York City) has revised the safety information for the drugs label and issued a letter to health care providers in light of five deaths from serious bacterial infection and sepsis following use of the medication abortion regimen.
-
New evidence indicates that women with benign breast disease have a higher risk for breast cancer, and that certain types of breast disease may predict the near-term development of breast cancer.
-
In reviewing the chart for your next patient, you note that she is a 28-year-old woman with epilepsy. What information do you need to provide her when it comes to contraceptive choices? Many family planning clinicians encounter this scenario. Epilepsy is one of the most common chronic health conditions affecting reproductive-age women.
-
Consider these facts: Women are the fastest-growing group in the United States with newly diagnosed HIV, and last year, an estimated 6,000-7,000 women with HIV gave birth.
-
The Food and Drug Administration (FDA) has strengthened the warning information on the labeling for the abortion drug mifepristone. The labeling change is in response to reports of infection, bleeding, and death among women who have taken the drug, according to the FDA.
